Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and HAIC vs FOLFOX for Advanced Intrahepatic Cholangiocarcinoma
NCT05535647Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in intrahepatic cholangiocarcinoma (ICC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
regorafenib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05535647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05535647.